Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-26-003803
Filing Date
2026-02-11
Accepted
2026-02-11 16:24:16
Documents
57
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q inbp20251231_10q.htm   iXBRL 10-Q 1136035
2 EXHIBIT 31.1 CERTIFICATION PURSUANT TO SECTION 302 CEO ex_913862.htm EX-31.1 13634
3 EXHIBIT 31.2 CERTIFICATION PURSUANT TO SECTION 302 CFO ex_913863.htm EX-31.2 15248
4 EXHIBIT 32.1 CERTIFICATION OF PERIODIC REPORT CEO ex_913864.htm EX-32.1 9184
5 EXHIBIT 32.2 CERTIFICATION OF PERIODIC REPORT CFO ex_913865.htm EX-32.2 7304
  Complete submission text file 0001437749-26-003803.txt   5824818

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inbp-20251231.xsd EX-101.SCH 44179
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inbp-20251231_cal.xml EX-101.CAL 39061
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20251231_def.xml EX-101.DEF 295828
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20251231_lab.xml EX-101.LAB 268440
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20251231_pre.xml EX-101.PRE 322261
60 EXTRACTED XBRL INSTANCE DOCUMENT inbp20251231_10q_htm.xml XML 1125562
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-31668 | Film No.: 26621079
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)